The Latest Cardiac and Vascular News
August 12, 2024 04:01 PM Eastern Daylight Time MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed […]
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™
– Data from the HuMAIN study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) will be presented in a Late Breaking Clinical Trial Plenary Session at the Heart Failure Society of America Annual Scientific Meeting – – Enrollment completed in Phase 2…
MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo’s 2024 Healthcare Conference on Wednesday, September 4, 2024. Mike Mahoney, chairman and chief executive officer, and Dr. Brad Sutton, chief medical officer, Atrial…
-FDA requires additional time to complete its review of ATEV™ (acellular tissue engineered vessel) BLA for the Treatment of Vascular Trauma-
SARASOTA, Fla., Aug. 13, 2024 /PRNewswire/ — Spectrum Dynamics Medical, a leading innovator in digital SPECT-CT imaging solutions, announced that its partnering with DEEPDENSE Medical, developing innovative AI-based clinical applications to revolutionize Cardiac and Spine disease…
• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
NEW YORK, Aug. 12, 2024 /PRNewswire/ — Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, announces expanded use of the CADScor System within wellness exams as part of self-insured companies’ health plans. As healthcare costs continue to rise, the CADScor System has…
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures
SAN DIEGO, Aug. 12, 2024 /PRNewswire/ — Provisio Medical, Inc., pioneers of Sonic Lumen Tomography™ (SLT) technology to provide real time blood vessel measurements during vascular interventions, today announced a key presentation featuring the Provisio™ SLT IVUS™ System during the annual…
